Vis enkel innførsel

dc.contributor.authorFeng, Xiaoshuang
dc.contributor.authorMuller, David C.
dc.contributor.authorZahed, Hana
dc.contributor.authorAlcala, Karine
dc.contributor.authorGuida, Florence
dc.contributor.authorSmith-Byrne, Karl
dc.contributor.authorYuan, Jian-Min
dc.contributor.authorKoh, Woon-Puay
dc.contributor.authorWang, Renwei
dc.contributor.authorMilne, Roger L.
dc.contributor.authorBassett, Julie K.
dc.contributor.authorLanghammer, Arnulf
dc.contributor.authorHveem, Kristian
dc.contributor.authorStevens, Victoria L.
dc.contributor.authorWang, Ying
dc.contributor.authorJohansson, Mikael
dc.contributor.authorTjønneland, Anne
dc.contributor.authorTumino, Rosario
dc.contributor.authorSheikh, Mahdi
dc.contributor.authorJohansson, Mattias
dc.contributor.authorRobbins, Hilary A.
dc.date.accessioned2023-10-18T07:40:48Z
dc.date.available2023-10-18T07:40:48Z
dc.date.created2023-06-30T11:09:38Z
dc.date.issued2023
dc.identifier.citationEBioMedicine. 2023, 92 .en_US
dc.identifier.issn2352-3964
dc.identifier.urihttps://hdl.handle.net/11250/3097171
dc.description.abstractBackground To evaluate whether circulating proteins are associated with survival after lung cancer diagnosis, and whether they can improve prediction of prognosis. Methods We measured up to 1159 proteins in blood samples from 708 participants in 6 cohorts. Samples were collected within 3 years prior to lung cancer diagnosis. We used Cox proportional hazards models to identify proteins associated with overall mortality after lung cancer diagnosis. To evaluate model performance, we used a round-robin approach in which models were fit in 5 cohorts and evaluated in the 6th cohort. Specifically, we fit a model including 5 proteins and clinical parameters and compared its performance with clinical parameters only. Findings There were 86 proteins nominally associated with mortality (p < 0.05), but only CDCP1 remained statistically significant after accounting for multiple testing (hazard ratio per standard deviation: 1.19, 95% CI: 1.10–1.30, unadjusted p = 0.00004). The external C-index for the protein-based model was 0.63 (95% CI: 0.61–0.66), compared with 0.62 (95% CI: 0.59–0.64) for the model with clinical parameters only. Inclusion of proteins did not provide a statistically significant improvement in discrimination (C-index difference: 0.015, 95% CI: −0.003 to 0.035). Interpretation Blood proteins measured within 3 years prior to lung cancer diagnosis were not strongly associated with lung cancer survival, nor did they importantly improve prediction of prognosis beyond clinical information. Funding No explicit funding for this study. Authors and data collection supported by the US National Cancer Institute (U19CA203654), INCA (France, 2019-1-TABAC-01), Cancer Research Foundation of Northern Sweden (AMP19-962), and Swedish Department of Health Ministry.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleEvaluation of pre-diagnostic blood protein measurements for predicting survival after lung cancer diagnosisen_US
dc.title.alternativeEvaluation of pre-diagnostic blood protein measurements for predicting survival after lung cancer diagnosisen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber0en_US
dc.source.volume92en_US
dc.source.journalEBioMedicineen_US
dc.identifier.doi10.1016/j.ebiom.2023.104623
dc.identifier.cristin2159770
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal